Protalix Q2 net loss narrows to $5.3M; PRX-102 Phase III CSR complete

Protalix BioTherapeutics, Inc.

2022-Q2 EPS reported -$0.16 revenue$24,838,000

Total revenues $8.8M ($3.4M product sales +$5.4M license/R&D), up 38% YoY.
Net loss $5.3M ($0.11/share) vs. $11.2M ($0.25/share) in Q2 2021.
Cash and equivalents $28.6M at June 30, 2022.
Phase III BALANCE trial CSR confirms positive topline results for PRX-102 in Fabry disease.
Appointed Shmuel Ben Zvi, Ph.D. to Board as Audit Committee Chairman.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.